Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
This article originally appeared in BMJ USA
In interim recommendations published by the US
Centers for Disease Control and Prevention (CDC) in the
Morbidity and Mortality Weekly Report,1 the
CDC recommended either ciprofloxacin or doxycycline as initial therapy for postexposure prophylaxis for prevention of infection with B anthracis. In a health
advisory issued on October 31, 2001, the CDC noted that ciprofloxacin
is effective against many common pathogens that are now resistant to
tetracyclines such as doxycycline. "To preserve the effectiveness of
ciprofloxacin against other infections," said the CDC, "use of
doxycycline for prevention of B anthracis infection is
reasonable."2
The CDC recommends ciprofloxacin as the antibiotic of choice for
initial prophylactic therapy among asymptomatic pregnant women exposed
to B anthracis. When the specific strain of B
anthracis has been shown to be penicillin-sensitive, prophylactic
therapy with amoxicillin may be considered.3
Readers should consult the CDC's website (www.bt.cdc.gov) for the most
current and detailed information and guidelines about managing
bioterrorism-related threats, exposures, and infections.
Editor
| 1. | US Centers for Disease Control and Prevention. Update: Investigation of anthrax associated with intentional exposure and interim public health guidelines, October 2001. MMWR 2001; 50: 889-893[Medline]. |
| 2. | US Centers for Disease Control and Prevention. Official CDC health advisory: Use of ciprofloxacin or doxycycline for postexposure prophylaxis for prevention of inhalational anthrax. www.bt.cdc.gov/DocumentsApp/Anthrax/10312001/han49.asp (accessed November 4, 2001) |
| 3. | US Centers for Disease Control and Prevention. Updated recommendations for antimicrobial prophylaxis among asymptomatic pregnant women after exposure to Bacillus anthracis. MMWR 2001; 50: 960[Medline]. |